HomeCompareSPVNF vs ABBV

SPVNF vs ABBV: Dividend Comparison 2026

SPVNF yields 37037.04% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPVNF wins by $2.4065325904961905e+22M in total portfolio value
10 years
SPVNF
SPVNF
● Live price
37037.04%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.4065325904961905e+22M
Annual income
$23,938,182,827,095,612,000,000,000,000.00
Full SPVNF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SPVNF vs ABBV

📍 SPVNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPVNFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPVNF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPVNF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPVNF
Annual income on $10K today (after 15% tax)
$3,148,148.15/yr
After 10yr DRIP, annual income (after tax)
$20,347,455,403,031,270,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SPVNF beats the other by $20,347,455,403,031,270,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPVNF + ABBV for your $10,000?

SPVNF: 50%ABBV: 50%
100% ABBV50/50100% SPVNF
Portfolio after 10yr
$1.2032662952480952e+22M
Annual income
$11,969,091,413,547,806,000,000,000,000.00/yr
Blended yield
99.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SPVNF
No analyst data
Altman Z
-94.6
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPVNF buys
0
ABBV buys
0
No recent congressional trades found for SPVNF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPVNFABBV
Forward yield37037.04%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$2.4065325904961905e+22M$102.3K
Annual income after 10y$23,938,182,827,095,612,000,000,000,000.00$24,771.77
Total dividends collected$2.4056969570736264e+22M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPVNF vs ABBV ($10,000, DRIP)

YearSPVNF PortfolioSPVNF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$3,714,404$3,703,703.70$11,550$430.00+$3.70MSPVNF
2$1,289,680,090$1,285,705,677.99$13,472$627.96+$1289.67MSPVNF
3$418,586,082,750$417,206,125,053.69$15,906$926.08+$418586.07MSPVNF
4$127,000,083,643,664$126,552,196,535,121.55$19,071$1,382.55+$127000083.62MSPVNF
5$36,020,244,067,789,990$35,884,353,978,291,260.00$23,302$2,095.81+$36020244067.77MSPVNF
6$9,550,369,884,101,736,000$9,511,828,222,949,202,000.00$29,150$3,237.93+$9550369884101.71MSPVNF
7$2,367,187,305,717,691,300,000$2,356,968,409,941,702,600,000.00$37,536$5,121.41+$2367187305717691.50MSPVNF
8$548,520,032,501,626,100,000,000$545,987,142,084,508,200,000,000.00$50,079$8,338.38+$548520032501626112.00MSPVNF
9$118,825,306,417,094,130,000,000,000$118,238,389,982,317,400,000,000,000.00$69,753$14,065.80+$118825306417094131712.00MSPVNF
10$24,065,325,904,961,905,000,000,000,000$23,938,182,827,095,612,000,000,000,000.00$102,337$24,771.77+$2.4065325904961905e+22MSPVNF

SPVNF vs ABBV: Complete Analysis 2026

SPVNFStock

Spectra7 Microsystems Inc. operates as an analog semiconductor company in Canada and China. The company offers virtual reality (VR) products, including VR7050 to enable lightweight and ultra-thin active interconnects for gesture recognition and motion control backhaul; augmented reality (AR) -Connect, an integrated cable, connector, and embedded chipset product line for AR vision systems and wearable computing devices; and DreamWeVR to support high-bandwidth, near-zero latency VR head-mounted displays, and AR glasses. It also provides GaugeChanger that allows copper to extend much longer lengths without the cost and power penalty of optics that are used in data centers; and USB 3.2 consumer interconnects for use in ultra-thin laptops, tablets, mobile devices, solid-state disks, and wearable computing devices. Spectra7 Microsystems Inc. is headquartered in San Jose, California.

Full SPVNF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SPVNF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPVNF vs SCHDSPVNF vs JEPISPVNF vs OSPVNF vs KOSPVNF vs MAINSPVNF vs JNJSPVNF vs MRKSPVNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.